Ex-BCG leader & David Sinclair’s COO on why evolution selected for aging, and how to get big pharma to invest into longevity therapies - Michael Ringel

Dr. Michael Ringel is a leader in pharma and biotech who spent over 25 years at Boston Consulting Group, where he served as managing director and senior partner, advising top pharma companies on R&D strategy.

Michael is now the Chief Operating Officer at Life Biosciences, a company founded by Dr. David Sinclair, to treat aging with partial epigenetic reprogramming. Earlier this year, Life Bio earned FDA clearance to proceed into human clinical trials with their lead candidate, marking the first time that humans will be administered an epigenetic reprogramming drug, which may be the holy grail of longevity.

Michael also sits on the US board of the Hevolution Foundation, an organization that is investing up to one billion dollars per year into longevity research, and is also on the board of the American Federation for Aging Research.

In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, how Life Bio is going into the clinic with the first epigenetic reprogramming therapies to reverse diseases of aging, and how to push the longevity field forward.

Why We Age by Michael Ringel: https://www.nature.com/articles/biorev202121

Hastings Center Report: https://onlinelibrary.wiley.com/doi/10.1002/hast.5007

And check out Michael's band on Spotify: https://open.spotify.com/artist/7hfcgDpc3SuCHfEAIhwWYr